606 related articles for article (PubMed ID: 19779305)
1. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
Garioud A; Seksik P; Chrétien Y; Corphechot C; Poupon R; Poupon RE; Chazouillères O
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):842-7. PubMed ID: 19779305
[TBL] [Abstract][Full Text] [Related]
2. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study.
Bergquist A; Glaumann H; Persson B; Broomé U
Hepatology; 1998 Feb; 27(2):311-6. PubMed ID: 9462625
[TBL] [Abstract][Full Text] [Related]
3. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy.
Brandsaeter B; Isoniemi H; Broomé U; Olausson M; Bäckman L; Hansen B; Schrumpf E; Oksanen A; Ericzon BG; Höckerstedt K; Mäkisalo H; Kirkegaard P; Friman S; Bjøro K
J Hepatol; 2004 May; 40(5):815-22. PubMed ID: 15094230
[TBL] [Abstract][Full Text] [Related]
4. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.
Rudolph G; Kloeters-Plachky P; Rost D; Stiehl A
Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):487-91. PubMed ID: 17489059
[TBL] [Abstract][Full Text] [Related]
5. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival.
Rudolph G; Gotthardt D; Kloeters-Plachky P; Rost D; Kulaksiz H; Stiehl A
J Hepatol; 2010 Aug; 53(2):313-7. PubMed ID: 20472317
[TBL] [Abstract][Full Text] [Related]
6. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence.
Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
Am J Surg Pathol; 2007 Jun; 31(6):907-13. PubMed ID: 17527079
[TBL] [Abstract][Full Text] [Related]
8. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
[TBL] [Abstract][Full Text] [Related]
9. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
[TBL] [Abstract][Full Text] [Related]
10. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis.
Tanaka A; Takamori Y; Toda G; Ohnishi S; Takikawa H
Liver Int; 2008 Aug; 28(7):983-9. PubMed ID: 18397233
[TBL] [Abstract][Full Text] [Related]
11. [Primary sclerosing cholangitis].
Boonstra K; Ponsioen CI; Rauws EA; Beuers U
Ned Tijdschr Geneeskd; 2010; 154():A1476. PubMed ID: 20619015
[TBL] [Abstract][Full Text] [Related]
12. High lifetime risk of cancer in primary sclerosing cholangitis.
Claessen MM; Vleggaar FP; Tytgat KM; Siersema PD; van Buuren HR
J Hepatol; 2009 Jan; 50(1):158-64. PubMed ID: 19012991
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis.
Boberg KM; Jebsen P; Clausen OP; Foss A; Aabakken L; Schrumpf E
J Hepatol; 2006 Oct; 45(4):568-74. PubMed ID: 16879890
[TBL] [Abstract][Full Text] [Related]
14. Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience.
Morris-Stiff G; Bhati C; Olliff S; Hübscher S; Gunson B; Mayer D; Mirza D; Buckels J; Bramhall SR
Dig Surg; 2008; 25(2):126-32. PubMed ID: 18446034
[TBL] [Abstract][Full Text] [Related]
15. A retrospective single-center review of primary sclerosing cholangitis in children.
Miloh T; Arnon R; Shneider B; Suchy F; Kerkar N
Clin Gastroenterol Hepatol; 2009 Feb; 7(2):239-45. PubMed ID: 19121649
[TBL] [Abstract][Full Text] [Related]
16. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
[TBL] [Abstract][Full Text] [Related]
17. Primary sclerosing cholangitis and malignancy.
Boberg KM; Lind GE
Best Pract Res Clin Gastroenterol; 2011 Dec; 25(6):753-64. PubMed ID: 22117640
[TBL] [Abstract][Full Text] [Related]
18. Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis.
Bergquist A; Broomé U
Best Pract Res Clin Gastroenterol; 2001 Aug; 15(4):643-56. PubMed ID: 11492973
[TBL] [Abstract][Full Text] [Related]
19. Management of primary sclerosing cholangitis.
Björnsson E
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):163-72. PubMed ID: 19305376
[TBL] [Abstract][Full Text] [Related]
20. Primary sclerosing cholangitis and cholangiocarcinoma.
Lazaridis KN; Gores GJ
Semin Liver Dis; 2006 Feb; 26(1):42-51. PubMed ID: 16496232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
